1. Introduction {#sec1-jcm-07-00179}
===============

Polycystic ovary syndrome (PCOS) is a common condition in humans, affecting 5--10% of women of reproductive age worldwide \[[@B1-jcm-07-00179]\]. It has serious reproductive implications, such as anovulatory infertility, oligomenorrhea, amenorrhea, hyperandrogenism, and pregnancy complications \[[@B2-jcm-07-00179]\]. It can also lead to mood disorders---according to a review report, the prevalence of depression among women with PCOS is 4 times greater than that among women without PCOS \[[@B3-jcm-07-00179]\]. Research over the last few decades has revealed that PCOS is strongly associated with metabolic disorders, including an increased risk of insulin resistance, type-2 diabetes, obesity, and cardiovascular diseases (worsening of lipid profile and blood-vessel function; high blood pressure) \[[@B4-jcm-07-00179]\]. Some reports have suggested that women with PCOS might have an increased prevalence of nonalcoholic fatty liver disease (NAFLD) and high C-reactive protein levels \[[@B5-jcm-07-00179],[@B6-jcm-07-00179],[@B7-jcm-07-00179]\].

Because PCOS reflects multiple abnormalities, current treatment protocols for PCOS aim to achieve different goals, including healthy weight control, amelioration of hyperandrogenic symptoms, management of underlying metabolic and reproductive complications, and improvement of quality of life. In PCOS, weight management through lifestyle and behavioral intervention is a first-line treatment strategy recommended by evidence-based guidelines \[[@B8-jcm-07-00179],[@B9-jcm-07-00179]\]. With regard to pharmaceutical treatments, oral contraceptives (OCs) are suggested as a first-line therapy for menstrual irregularities and hyperandrogenism \[[@B10-jcm-07-00179],[@B11-jcm-07-00179]\]. However, OCs are not appropriate for women pursuing pregnancy, and they might cause weight gain, thus exacerbating the PCOS \[[@B12-jcm-07-00179]\]. For fertility needs, clomiphene induces ovulation through the release of the gonadotropin-releasing hormone and, subsequently, gonadotropin from the anterior pituitary. However, pregnancy rates in clomiphene therapy have remained low among overweight women with PCOS \[[@B13-jcm-07-00179],[@B14-jcm-07-00179],[@B15-jcm-07-00179]\]. Management approaches for metabolic disorders include treatment with metformin and thiazolidinediones, which appear to decrease insulin levels and hyperandrogenemia in women with PCOS \[[@B16-jcm-07-00179]\]. However, use of metformin is associated with a high incidence of gastrointestinal adverse effects \[[@B17-jcm-07-00179]\]. Moreover, because of the possibility of cardiovascular adverse events, thiazolidinediones are not suggested for nondiabetic women with PCOS \[[@B18-jcm-07-00179],[@B19-jcm-07-00179]\].

It is a common practice in Chinese society to receive treatment with herbal remedies or acupuncture for obstetrical and gynecological conditions, such as uterine fibroids, dysmenorrhea, climacteric syndrome, premenstrual syndrome, and infertility. Previous studies have reported that, in women with PCOS, treatment with Chinese herbal medicine in conjunction with clomiphene citrate provides higher pregnancy rates than treatment with clomiphene citrate alone \[[@B20-jcm-07-00179],[@B21-jcm-07-00179],[@B22-jcm-07-00179],[@B23-jcm-07-00179]\]. Moreover, acupuncture therapy might increase menstrual frequency and ovulation rates \[[@B24-jcm-07-00179],[@B25-jcm-07-00179],[@B26-jcm-07-00179],[@B27-jcm-07-00179],[@B28-jcm-07-00179]\]. Research in diabetes and insulin resistance has shown progress in recent years. Integrating traditional Chinese medicine (TCM) healthcare into diabetes care has been shown to decrease the risk of developing kidney failure and stroke in type-2 diabetes mellitus \[[@B29-jcm-07-00179],[@B30-jcm-07-00179]\]. Therefore, we hope to understand the clinical characteristics and treatment behavior of women with PCOS with regard to TCM.

In Taiwan, TCM has been reimbursed under the current Taiwanese National Health Insurance (NHI) system since 1996. At the end of 2010, approximately 99.89% of the total 23 million population were enrolled in the NHI \[[@B31-jcm-07-00179]\]. Although the broadly defined category of TCM includes Chinese herbal medicine, proprietary Chinese medicine, acupuncture, moxibustion, manipulation, mediation, Qi management, and other practices, the NHI program covers only three major modalities: (1) Chinese herbal products (CHPs) manufactured by GMP (good manufacturing practice)-certified pharmaceutical companies (e.g., concentrated scientific TCM granules and finished herbal products); (2) acupuncture, moxibustion, and cupping therapy; and (3) manipulative therapy (including acupressure, chiropractic, and tui na massage) \[[@B32-jcm-07-00179]\]. All data regarding the use of TCM in Taiwan have been collected in the National Health Insurance Research Database (NHIRD). However, there is a lack of large-scale statistical data on the clinical usage of TCM in PCOS. Therefore, this study aimed to understand the TCM prescription patterns and combinations among women with PCOS in Taiwan in order to gain information for further pharmacologic experiments and clinical trials.

2. Materials and Methods {#sec2-jcm-07-00179}
========================

2.1. Data Source {#sec2dot1-jcm-07-00179}
----------------

This study used reimbursement claims data deposited in the NHIRD, which has been implemented by the Taiwan government since 1996. The NHIRD contains longitudinal data of a cohort comprising 1 million participants randomly selected from among insurance beneficiaries between January 1997 and December 2013 (LHID2000). These datasets include information on patient characteristics; date of clinic visit; diagnosis codes in accordance with the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) system; prescription details for Chinese herbal medicine; and detailed claims data for examination and disease management for all admitted patients and outpatients. In this study, NHRI datasets from 1997 to 2010 were selected for use as the research database, and patients were followed to December 2013. This study was approved by the institutional review board of China Medical University in central Taiwan (CMUH104-REC2-115).

2.2. Study Design and Population {#sec2dot2-jcm-07-00179}
--------------------------------

The flowchart for selection of PCOS cases is shown in [Figure 1](#jcm-07-00179-f001){ref-type="fig"}. This study included patients who were diagnosed with PCOS (ICD-9-CM code: 256.4) in NHIRD from 1 January 1997 to 31 December 2010. All cases had undergone gynecologic ultrasonography (19003C) or blood testing for testosterone or 17-hydroxyprogesterone levels (09121C, 09121B, or 09109C) within a year of diagnosis. We excluded the beneficiaries less than 18 years old (*n* = 508), if sex information indicated male, or if there was missing information for sex or birthday (*n* = 186). At last, participants who withdrew from the NHI were also excluded from our study (*n* = 20). Patients who had been receiving TCM between the date of initial diagnosis of PCOS and the study endpoint were included in the TCM users group (*n* = 5962). The first diagnosis date of accepted TCM after initial PCOS diagnosis date was considered the index date; patients with PCOS who had not taken any TCM after the initial PCOS diagnosis date were included in the non-TCM cohort (*n* = 720).

2.3. Potential Confounders {#sec2dot3-jcm-07-00179}
--------------------------

We identified any potential confounders for PCOS diagnosed before the index date, including the following comorbidities: diabetes mellitus (ICD-9-CM: 250.x), infertility female (628.x), hirsutism (704.1), acne varioliformis (706.0 or 706.1), obesity (278), lipid metabolism disorders (272.0, 272.1, 272.2, 272.3 or 272.4), major depression (296.2x or 296.3x), anxiety (300.x), and amenorrhea (626.0 or 626.1).

2.4. Statistical Analysis {#sec2dot4-jcm-07-00179}
-------------------------

Mean values and standard deviation were described for continuous variables, and percentages were described for categorical variables. Intergroup comparison was performed by the Student t-test and chi-square test for continuous and categorical variables, respectively. Statistical analysis was performed using SAS 9.4 (SAS Institute, Cary, NC, USA) software. Two-tailed *p* values \< 0.05 indicated statistical significance.

3. Results {#sec3-jcm-07-00179}
==========

3.1. Subject Characteristics {#sec3dot1-jcm-07-00179}
----------------------------

The present analysis included 6682 subjects who were newly diagnosed with PCOS during 1997--2010 ([Table 1](#jcm-07-00179-t001){ref-type="table"}). All enrolled patients had undergone gynecologic ultrasonography or blood testing for serum testosterone levels. Among the enrolled subjects, while 720 did not receive TCM for treatment of PCOS in the follow-up period, 5962 had received TCM for PCOS treatment. In both cohorts (TCM users and nonusers), the highest proportion of patients were in the age group of 18--29 years. There was no substantial difference in urbanization level or standard of hospitals (where PCOS was diagnosed) between the two groups. With regard to comorbidities, TCM users had a higher prevalence of infertility (*p* = 0.027), amenorrhea (*p* \< 0.0001), and anxiety (*p* = 0.0002) than TCM nonusers. The prevalence of diabetes mellitus, obesity, lipid metabolism disorders, and major depression was similar in both groups.

3.2. Distribution of Types of TCM {#sec3dot2-jcm-07-00179}
---------------------------------

The results of analysis of medical records in the TCM outpatient departments revealed that 50.37% of patients with PCOS were treated with herbal medicine only, 0.18% with acupuncture or manipulative therapy only, and 49.45% with combination treatment. With regard to the frequency of hospital visits, most patients (60.32%) had visited TCM clinics less than three times. Approximately 25.9% of the patients had received TCM treatment more than six times ([Table 2](#jcm-07-00179-t002){ref-type="table"}).

3.3. TCM Prescription Patterns for PCOS {#sec3dot3-jcm-07-00179}
---------------------------------------

We conducted an analysis to investigate the prescription patterns of CHPs and identified 10 of the most commonly prescribed Chinese herbal formulas and single herbs ([Table 3](#jcm-07-00179-t003){ref-type="table"}). The most commonly prescribed Chinese herbal formula was Jia-Wei-Xiao-Yao-San (JWXYS; Supplemented Free Wanderer Powder), followed by Gui-Zhi-Fu-Ling-Wan (GZFLW; Cinnamon Twig and Poria Pill), and Dang-Gui-Shao-Yao-San (Lesser Abdomen Stasis-Expelling Decoction). The most commonly prescribed single herb was Xiang-Fu (*Cyperus rotundus* L.), followed by Da-Huang (*Rheum officinale* Baill.) and Yi-Mu-Cao (*Leonurus artemisia* (Lour.) S. Y. Hu).

3.4. Frequency Distribution of Disease Categories in TCM and Non-TCM Visits {#sec3dot4-jcm-07-00179}
---------------------------------------------------------------------------

We analyzed the frequency distribution of disease categories for TCM and non-TCM visits on the basis of ICD-9-CM codes from the claims data. Among TCM users, genitourinary diseases (99.21%) were the most common reasons for visiting TCM clinics, followed by digestive (99.14%) and respiratory (99.03%) disorders. In case of TCM nonusers visiting Western medical clinics, digestive disorders (95.42%) were more frequent than genitourinary diseases (94.58) and respiratory disorders (94.44%). The disease patterns among TCM users who visited clinics were similar to those among TCM nonusers ([Table 4](#jcm-07-00179-t004){ref-type="table"}).

4. Discussion {#sec4-jcm-07-00179}
=============

In 2012, the proceedings of a National Institutes of Health (NIH) workshop suggested that the Rotterdam 2003 criteria be used for diagnosis of PCOS. The Rotterdam criteria recommended that PCOS be diagnosed on the basis of the presence of two of the following three features: oligo- and/or anovulation, clinical and/or biochemical hyperandrogenism, and polycystic ovaries identified by ultrasonography. Thus, in the present study, we selected cases from the NHIRD on the basis of examination codes indicating gynecologic ultrasonography and blood testing for testosterone level.

This study is the first large-scale report on the utilization patterns of TCM by patients newly diagnosed with PCOS. It involved analysis of claims data from TCM and non-TCM clinic visits covered by the NHI in Taiwan. According to a previous study involving the general population in Taiwan \[[@B33-jcm-07-00179]\], 31.2% of patients used TCM in 2010, with 59.3% of TCM users being women. The study also found that herbal remedies were the most commonly used therapeutic approach in TCM (58.2%), with the frequency of combination therapy with herbal remedies being 3.8%. The present findings revealed that patients with PCOS had a relatively high tendency to consult TCM practitioners (89.22%). This might be attributable to the limited efficacy or adverse effects of current management options for PCOS in Western medicine. The use of combination therapy was also substantially high among patients with PCOS in our study (49.45%; [Table 3](#jcm-07-00179-t003){ref-type="table"}). A recent animal study showed that combination treatment with Chinese medicinal herbs and acupuncture enhances the curative effects of the former in PCOS treatment, and that acupuncture has a positive effect on improving the absorption of herbal extracts \[[@B34-jcm-07-00179]\].

In the present study, the most common herbal formula used for PCOS treatment was found to be JWXYS, a classical TCM formula containing 10 herbs. The formula was originally recorded in *Nei Ke Zhai Zhe Yao* (Internal Medicine Abstract), written by imperial physician Xue Ji during the rule of the Ming dynasty in ancient China. In modern clinical therapy, JWXYS plays a vital role in treatment of anxiety, irritability, stress, depression, premenstrual tension, climacteric syndrome, and infertility \[[@B35-jcm-07-00179],[@B36-jcm-07-00179]\]. In animal models, JWXYS appears to have antidepressant effects; in a previous study, JWXYS, at 20 times its standard dose, reversed the impairment of neurogenesis in the hippocampus of stressed rats \[[@B37-jcm-07-00179]\]. Another study found that JWXYS increases plasma tumor necrosis factor (TNF)-α levels in depressed menopausal patients \[[@B38-jcm-07-00179]\]. In a previous randomized controlled trial, JWXYS was found to show a certain effect on improving the quality of life and alleviating depressive and obsessive-compulsive behavior, phobic anxiety, and somatic symptoms in patients with generalized anxiety disorder \[[@B39-jcm-07-00179]\].

The second most common herbal formula for PCOS treatment among the present study population was GZFLW, which has been widely used in Asiatic countries for centuries. The formula was originally recorded in *Shang Han Za Bing Lun* (Treatise on Cold Pathogens and Miscellaneous Diseases), written by Zhang Zhong jing at the end of the Eastern Han dynasty between 200 and 205 AD. It is a formula used to invigorate blood, transform blood stasis, and reduce fixed abdominal masses \[[@B40-jcm-07-00179]\]. In previous animal studies, GZFLW was found to exert beneficial effects on symptoms associated with type-2 diabetes. In rats with diabetes, GZFLW was demonstrated to exert protective effects against vascular injury \[[@B41-jcm-07-00179],[@B42-jcm-07-00179]\] and delay the development of diabetic nephropathy \[[@B43-jcm-07-00179]\]. The formula also causes a significant decrease in serum total cholesterol and triglycerides and hepatic total cholesterol levels. Additionally, GZFLW has a favorable effect on impaired glucose metabolism in type-2 diabetes by improving glucose intolerance, and it has been suggested that some of this effect is derived from the reduction of TNF-α content in skeletal muscle \[[@B42-jcm-07-00179]\]. It has also been shown to decrease blood glucose and serum urea nitrogen and creatinine levels in rats with diabetic nephropathy. Moreover, histological findings have shown that GZFLW inhibits the development of glomerular lesions, including diffuse, nodular, fibrin-cap, capsular-drop lesions, and arteriolar hyalinosis \[[@B43-jcm-07-00179]\]. In a small retrospective study, GZFLW treatment led to a significant improvement in liver injury outcomes and blood cholesterol levels in all patients with NAFLD \[[@B44-jcm-07-00179]\].

The third most commonly prescribed herbal formula for PCOS treatment among the present study population was Dang-Gui-Shao-Yao-San. It has been found to suppress uterine contractions through antagonistic action on both prostaglandin F2α and acetylcholine \[[@B45-jcm-07-00179]\] and can be used to treat dysmenorrhea and abdominal pain. Wen-Jing-Tang (WJT), the fourth most commonly prescribed herbal formula for PCOS treatment ([Table 3](#jcm-07-00179-t003){ref-type="table"}), is traditionally used to treat amenorrhea, excessive bleeding, and infertility during menses due to deficiency-cold in the Chong and Ren channels, which leads to Qi and blood stagnation. Clinically, WJT has also been shown to cause a significant decrease in plasma luteinizing hormone (LH) levels in anovulatory patients with high plasma LH concentrations, including those with PCOS \[[@B46-jcm-07-00179]\]. Furthermore, WJT improves the functioning of human granulosa cells in vitro by enhancing 17β-estradiol and progesterone secretion \[[@B47-jcm-07-00179]\].

The fifth most common herbal formula prescribed for PCOS treatment was Ma-Zi-Ren-Wan (MZRW), also known as hemp seed pill. According to the findings of modern pharmaceutical studies, MZRW has shown to be effective and safe for alleviating the symptoms of functional constipation \[[@B48-jcm-07-00179],[@B49-jcm-07-00179],[@B50-jcm-07-00179]\]. In an 18-week prospective, randomized, double-blind, placebo-controlled clinical study involving 120 patients with constipation, MZRW was found to increase complete spontaneous bowel movement and decrease straining at evacuation, without any serious adverse effects \[[@B48-jcm-07-00179]\].

In the case of single herbs, Xiang-Fu was the most commonly prescribed herb for PCOS treatment among the present study population. It has been reported to exhibit antidepressant activity in the forced swimming test in experimental animal models \[[@B51-jcm-07-00179]\]. Da-Huang, the second most commonly prescribed single herb, contains abundant emodin, which has been proposed as a possible treatment for type-2 diabetes and other metabolic disorders. This effect is likely associated with activation of the peroxisome proliferator-activated receptor-γ and adenosine monophosphate-activated protein kinase (AMPK) signaling pathways \[[@B52-jcm-07-00179],[@B53-jcm-07-00179],[@B54-jcm-07-00179],[@B55-jcm-07-00179],[@B56-jcm-07-00179],[@B57-jcm-07-00179]\]. Wang et al. demonstrated that, over long-term treatment, emodin (3 μM) is a potent and selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1 and can ameliorate metabolic disorders in mice with diet-induced obesity \[[@B58-jcm-07-00179]\]. In hypercholesterolemic rats, emodin has shown hypocholesterolemic effects that might be mediated by its ability to bind bile salts and subsequently increase the expression levels of cholesterol 7α-hydroxylase \[[@B59-jcm-07-00179]\].

Yi-Mu-Cao, also known as Chinese motherwort, was the third most commonly prescribed single herb for PCOS treatment. Traditionally, Yi-Mu-Cao has been described to play a role in promoting blood flow to regulate menstruation. The herb can be used to treat menstrual disorders. In a modern animal study on diabetic mice, treatment with motherwort extract SCM-198 (4-guanidino-*n*-butyl syringate) for 3 weeks caused a decrease in fasting blood glucose and plasma triacylglycerol levels and an increase in high-density lipoprotein and plasma insulin concentrations. The extract was reported to exhibit anti-inflammatory activity and have an ameliorating effect on diabetic symptoms through inhibition of the nuclear factor-κB/IκB kinase pathway \[[@B60-jcm-07-00179]\]. In atherosclerotic rabbits, SCM-198 has been shown to ameliorate the progression of atherosclerotic lesions by inhibiting inflammatory factors and oxidative stress \[[@B61-jcm-07-00179]\]. Leonurine---another extract of motherwort---has also been found to have an antidepressant effect in mice, effectively restoring 5-hydroxytryptamine, noradrenaline, and dopamine levels in the hippocampus and prefrontal cortex and ameliorating hippocampal neuronal damage in mice with chronic mild stress \[[@B62-jcm-07-00179]\]. Yan-Hu-Suo (*Corydalis yanhusuo* W. T. Wang), the most common single herb used for treating dysmenorrhea, has been reported to demonstrate significant analgesic effects in human clinical studies \[[@B63-jcm-07-00179],[@B64-jcm-07-00179]\]. A previous study described a compound in Yan-Hu-Suo---dehydrocorybulbine---which showed antinociceptive effects owing to its interaction with dopamine-2 receptors \[[@B65-jcm-07-00179]\].

The fifth most common single herb used for PCOS treatment was Dan-Shen, the dried root of the plant *Salvia miltiorrhiza* Bge. The main active components in Dan-Shen injection are danshensu, salvianolic acids A and B (SalA and B), rosmarinic acid, and prolithospermic acid \[[@B66-jcm-07-00179]\]. Recent studies have reported that SalB could potentially be useful for treatment of insulin resistance, obesity, and type-2 diabetes \[[@B67-jcm-07-00179],[@B68-jcm-07-00179],[@B69-jcm-07-00179],[@B70-jcm-07-00179],[@B71-jcm-07-00179]\]. Additionally, SalB has demonstrated the ability to protect pancreatic beta cells \[[@B71-jcm-07-00179]\]. Both SalB and A have also shown hepatoprotective effects in several clinical trials on NAFLD \[[@B72-jcm-07-00179],[@B73-jcm-07-00179],[@B74-jcm-07-00179],[@B75-jcm-07-00179],[@B76-jcm-07-00179],[@B77-jcm-07-00179]\].

From these results, we have a preliminary understanding of the usage and prescription patterns of TCM for PCOS treatment. Many among these prescription herbs have shown hepatoprotective effects, as well as beneficial effects in treatment of hyperglycemia, insulin intolerance, dyslipidemia, and anovulation. We list the possible pharmacological effects or mechanism of the herbal formulas and single herbs in [Table 5](#jcm-07-00179-t005){ref-type="table"}. These findings indicate that Chinese herbal medicine might serve as a potentially effective therapeutic option for PCOS. Therefore, future studies should analyze the association between TCM intervention and PCOS symptoms, such as menstrual regularity, hirsutism, acne, obesity, depression, low ovulation, pregnancy, and live-birth rates. In addition to symptom assessment, serological markers can also be listed among analytical indicators for assessing the benefits of Chinese medicine in PCOS treatment.

The present study has the following strengths. First, confirming the prescription patterns of TCM through the health insurance database helped avoid the possibility of memory bias associated with questionnaire-based investigation. Second, all subjects enrolled in this study had undergone blood testing or gynecologic ultrasonography before being diagnosed with PCOS by a qualified physician. However, there are several limitations to this study. Details regarding disease severity and treatment efficacy were not known because of the lack of imaging and laboratory data in the NHIRD. Moreover, Chinese herbal decoctions or remedies that were purchased directly from TCM herbal pharmacies were not covered by NHI, which might have led to underestimation of the frequency of TCM use. However, because the NHI program allows Chinese herbal remedies to be availed at a relatively low cost, the proportion of patients taking herbal medicine outside the NHI system is relatively low. Moreover, patients might be prescribed other Western medicines or self-purchase supplements for treating PCOS or other diseases during the follow-up period. The possibility of interaction of different types of medicines also requires longer following and analysis.

5. Conclusions {#sec5-jcm-07-00179}
==============

This study is the first large-scale survey to analyze TCM utilization patterns among women with PCOS in Taiwan. Jia-Wei-Xiao-Yao-San was the most commonly used TCM formula, while Xiang-Fu was the most commonly used single herb in our dataset. In addition, we found that the top five most commonly prescribed single herbs and herbal formulas have shown promise in treating symptoms associated with PCOS. Further pharmacological investigations and clinical trials could be developed on the basis of the present findings.

This study was based in part on data from the National Health Insurance Research Database, provided by the National Health Insurance Administration, Ministry of Health and Welfare, and managed by National Health Research Institutes. The interpretation and conclusions contained herein do not represent those of the National Health Insurance Administration, Ministry of Health and Welfare, or National Health Research Institutes.
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jcm-07-00179-t001_Table 1

###### 

Demographic characteristics of the patients newly diagnosed with PCOS in Taiwan in 1997--2010.

  Variable                                                                                    Without TCM   With TCM      *p* Value            
  ------------------------------------------------------------------------------------------- ------------- ------------- ------------ ------- -------------
  **Age at baseline**                                                                                                                          0.0654 \*
   18--29                                                                                     395           54.86         3539         59.36   
   30--39                                                                                     265           36.81         1991         33.39   
   Older than 40                                                                              60            8.33          432          7.25    
   Mean(SD)                                                                                   29.77(6.93)   29.09(6.67)   0.0094 ^‡^           
  **Urbanization**                                                                                                                             0.7906 \*
   1 (highest)                                                                                236           32.78         1972         33.08   
   2                                                                                          230           31.94         1824         30.59   
   3                                                                                          116           16.11         984          16.5    
   4                                                                                          89            12.36         707          11.86   
   4+ (lowest)                                                                                49            6.81          475          7.97    
  **Hospital level (where diagnosed with PCOS)**                                                                                               0.2209 \*
   Medical center                                                                             170           23.64         1326         22.24   
   Regional hospital                                                                          281           39.08         2172         36.43   
   District hospital                                                                          118           16.41         1070         17.95   
   Physician clinics                                                                          150           20.86         1394         23.38   
  **Baseline comorbidity**                                                                                                                     
   Diabetes mellitus                                                                          43            5.97          441          7.4     0.1636 \*
   Infertility female                                                                         129           17.92         1362         22.84   0.0027 \*
   Hirsutism                                                                                  1             0.14          27           0.45    0.3567 \*
   Acne varioliformis                                                                         227           31.53         1950         32.71   0.5236 \*
   Obesity                                                                                    14            1.94          159          2.67    0.2489 \*
   Disorders of lipoid metabolism                                                             42            5.83          294          4.93    0.2954 \*
   Major depression                                                                           16            2.22          137          2.3     0.898 \*
   Anxiety                                                                                    60            8.33          786          13.18   0.0002 \*
   Amenorrhea                                                                                 218           30.28         2630         44.11   \<0.0001 \*
  Interval between onset of PCOS disease and the first TCM consultation, days mean (median)                 530.88(246)                        

^‡^*t* test; \* chi-square test.

jcm-07-00179-t002_Table 2

###### 

Distribution of Chinese medicine according to type of Chinese medicine treatment received in women with PCOS, stratified by number of outpatient visits.

  Number of TCM Visits (Times/per Year)   Only Chinese Herbal Remedies   Only Acupuncture or Traumatology   Combination of Both Treatments   Total of TCM (*n* = 5962)
  --------------------------------------- ------------------------------ ---------------------------------- -------------------------------- ---------------------------
  1--3                                    2016 (67.13)                   11 (100)                           1569 (53.22)                     3596 (60.32)
  4--6                                    361 (12.02)                    0                                  461 (15.64)                      822 (13.79)
  \>6                                     626 (20.85)                    0                                  918 (31.14)                      1544 (25.90)

jcm-07-00179-t003_Table 3

###### 

Ten most common herbal formulas prescribed.

  Herbal Formula                                     Frequency   Number of Person-Days   Average Daily Dose   Average Duration for Prescription
  -------------------------------------------------- ----------- ----------------------- -------------------- -----------------------------------
  Single Chinese herb                                                                                         
   Xiang-Fu (Cyperus rotundus L.)                    12,375      86,491                  1.0                  7.0
   Da-Huang (Rheum officinale Baill.)                11,350      83,520                  0.7                  7.4
   Yi-Mu-Cao (Leonurus artemisia (Lour.) S. Y. Hu)   10,824      77,687                  1.1                  7.2
   Yan-hu-suo (Corydalis yanhusuo W. T. Wang)        9889        68,526                  1.1                  6.9
   Dan-shen (Salvia miltiorrhiza Bge.)               8072        61,438                  1.1                  7.6
   Gan-Cao (Glycyrrhiza uralensis Fisch.)            7818        53,026                  0.9                  6.8
   Tu-Si-Zi (Cuscuta chinensis Lam.)                 7178        52,268                  1.3                  7.3
   Huang-Qin (Scutellaria baicalensis Georgi)        7616        52,213                  1.2                  6.9
   Bei-Mu (Fritillaria thunbergii Miq.)              5860        39,858                  1.1                  6.8
   Du-Zhong (Eucommia ulmoides Oliv.)                5414        39,649                  1.1                  7.3
  Combined Chinese herb                                                                                       
   Jia-Wei-Xiao-Yao-San                              21,305      15,3952                 4.3                  7.2
   Gui-Zhi-Fu-Ling-Wan                               8779        62,294                  3.9                  7.1
   Dang-Gui-Shao-Yao-San                             8470        58,510                  4.4                  6.9
   Wen-Jing-Tang                                     7970        58,018                  4.2                  7.3
   Ma-Zi-Ren-Wan                                     6850        51,079                  2.7                  7.5
   Chuan-Xiong-Cha-Tiao-San                          5643        36,836                  3.9                  6.5
   Gui-Pi-Tang                                       4895        36,050                  4.3                  7.4
   Ger-Gen-Tang                                      5471        35,096                  4.3                  6.4
   Shao-Fu-ZhuYu-Tang                                4994        34,233                  3.8                  6.9
   Xue-Fu-Zhu-Yu-Tang                                4473        33,638                  3.8                  7.5
  List according to person-days                                                                               

jcm-07-00179-t004_Table 4

###### 

The distribution of TCM and non-TCM users by major disease categories/diagnosis in patients with PCOS.

  Disease (ICD-9-CM)                                                               Without TCM (*n* = 720)   With TCM (*n* = 5962)   *p* Value            
  -------------------------------------------------------------------------------- ------------------------- ----------------------- ----------- -------- ----------
  Infectious and parasitic disease (001--139)                                      439                       60.97                   4433        74.35    \<0.0001
  Neoplasms (140--239)                                                             324                       45.00                   3384        56.76    \<0.0001
   Malignant (140--208)                                                            19                        2.64                    257         4.31     0.0332
   Benign (210--229)                                                               313                       43.47                   3242        54.38    \<0.0001
  Endocrine, nutritional, and metabolic disease and immunity disorder (240--279)   720                       100.00                  5962        100.00   \-
  Blood and blood-forming organs (280--289)                                        136                       18.89                   1482        24.86    0.0004
  Mental disorder (290--319)                                                       156                       21.67                   2243        37.62    \<0.0001
  Nervous system (320--389)                                                        532                       73.89                   5232        87.76    \<0.0001
  Circulatory system (390--459)                                                    200                       27.78                   2415        40.51    \<0.0001
  Respiratory system (460--519)                                                    680                       94.44                   5904        99.03    \<0.0001
  Digestive system (520--579)                                                      687                       95.42                   5911        99.14    \<0.0001
  Genitourinary system (580--629)                                                  681                       94.58                   5915        99.21    \<0.0001
  Complications of pregnancy, childbirth, and the puerperium (630--676)            309                       42.92                   3015        50.57    0.0001
  Skin and subcutaneous tissue (680--709)                                          595                       82.64                   5553        93.14    \<0.0001
  Musculoskeletal system and connective tissue (710--739)                          394                       54.72                   4964        83.26    \<0.0001
  Congenital anomalies (740--759)                                                  30                        4.17                    455         7.63     0.0007
  Certain conditions originating in the perinatal period (760--779)                122                       16.94                   1053        17.66    0.6329
  Symptoms, signs, and ill-defined conditions (780--799)                           607                       84.31                   5772        96.81    \<0.0001
  Injury and poisoning (800--999)                                                  422                       58.61                   5129        86.03    \<0.0001
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###### 

Possible pharmacological effects or mechanisms of the most common herbal formulas and single herbs for the treatment of patients with PCOS.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Chinese Herbal Products   Model/Design                                        Possible Pharmacological Effects or Mechanism                                     
  ------------------------- --------------------------------------------------- --------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------
  Herbal formulas                                                                                                                                                 

  Jia-Wei-Xiao-Yao-San      Multicenter, Double blind, Placebo controlled RCT   Antidepressant effects                                                            Improve quality of life, reduce depressive, obsessive-compulsive, somatic symptoms of generalized anxiety disorder

  Stressed rats             Antidepressant effects                              Reverse the impairment of neurogenesis in the hippocampus                         

  Gui-Zhi-Fu-Ling-Wan       Retrospective study                                 Anti-inflammation\                                                                Reduction in liver injury tests and blood cholesterol
                                                                                Hypolipidemic effects                                                             

  Diabetic rats             Anti-diabetic effects\                              Improve glucose intolerance, decrease in serum total cholesterol and TG levels\   
                            Hypolipidemic effects                               Delay the development of diabetic nephropathy                                     

  Dang-Gui-Shao-Yao-San     Rats                                                Analgesic effect                                                                  Suppress uterine contraction through antagonistic action on both prostaglandin F2α and acetylcholine

  Wen-Jing-Tang             Clinical Trial                                                                                                                        Decrease in plasma LH level in anovulatory patients including those with PCOS

  Human granulosa cells                                                         Enhancing 17β-estradiol and progesterone secretion                                

  Ma-Zi-Ren-Wan             Double blind, Placebo controlled RCT                                                                                                  Increase complete spontaneous bowel movement and decrease straining at evacuation

  Single herbs                                                                                                                                                    

  Xiang-Fu                  Rats                                                Antidepressant                                                                    Had antidepressant activity in the forced swimming test

  Da-Huang                  Mice                                                Hypocholesterolemic effects                                                       Activation of the PPAR-γ and AMPK signaling pathways

  Yi-Mu-Cao                 Mice                                                Potential to treat insulin resistance, and type-2 diabetes                        Through inhibition of the NF-κB/IκB kinase pathway

  Yan-hu-suo                Mice                                                Analgesic effects                                                                 Antinociceptive effect due to interaction with D2 receptors

  Dan-shen                  Rats                                                Potential to treat insulin resistance, obesity, and type-2 diabetes               SalB: Increased phosphorylated AMPK protein expression, GLUT 4 and glycogen synthase protein expressions

  Rats                      Hepatoprotective effects                            SalA: Suppressing ROS, MDA; preventing the decreased expression of SOD\           
                                                                                SalB: Through SIRT1-mediated HMGB1 deacetylation                                  
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
